FAM13A-AS1

Across TCGA pan-cancer cohorts, FAM13A-AS1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of FAM13A-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FAM13A-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FAM13A-AS1 is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

KIRC, BRCA, and LUSC are the cancer types where FAM13A-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAM13A-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.726	<.001	12	view →
BRCA	All	III,IV	−0.785	<.001	6	view →
LUSC	All	All	−0.496	<.001	5	view →
LUAD	Male	III,IV	−0.613	.006	4	view →
THCA	All	All	−0.282	.001	4	view →
CHOL	Female	All	+1.033	<.001	3	view →
PRAD	All	All	+0.294	.004	2	view →
UCEC	All	IV	−0.135	.022	2	view →
LIHC	All	All	+0.115	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

FAM13A-AS1–KIRC

Open the KIRC breakdown →